Tenofovir-Emtricitabine (TDF-FTC) is known to cause bone loss in about 1–3% of HIV treated patients. Current studies lack evidence in minority groups and long-term bone loss effects in PrEP patients.
Setting
To address the risk of osteopenia/osteoporosis in patients on TDF-FTC therapy for HIV PrEP and to address the breakthrough incidence of HIV.
Methods
A retrospective analysis was performed in Kaiser Permanente patients from 2012–2021. Patients on TDF-FTC for PrEP without any prior history of osteopenia/osteoporosis (N = 7698) were analyzed to determine the relationship between PrEP adherence and osteopenia/osteoporosis. Descriptive statistics and Cox proportional hazards model were used to compare and analyze patient characteristics between those who developed osteopenia/osteoporosis and those who didn’t.
Results
3% were found to have osteopenia/osteoporosis. Patients who developed osteopenia/osteoporosis were more likely to have a proportion of days covered (PDC) ratio ≥90%, older, had history of Hep B, DM, CVD, CKD, hypertension, and baseline eGFR ≥90 mL/min/1.73 m2. Kaplan-Meier curve showed the event-free rate of osteopenia/osteoporosis decreased with time, with a greater reduction in patients with high adherence. Survival analysis showed only PDC of ≥90% was significantly associated with the risk of osteopenia/osteoporosis when adjusted. No incidence of HIV infection was detected.
Conclusions
This retrospective cohort analysis showed that TDF-FTC offered superior PrEP protection. Although high PrEP adherence ensured protection from HIV infection, it was significantly associated with a higher risk of developing osteopenia/osteoporosis. These findings suggest that routine check-ups for osteopenia/osteoporosis may be needed.
Truvada [package insert]. Foster City, CA: Gilead Pharmaceuticals Inc., 2016.
2.
McCormackSDunnDTDesaiM, et al.Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomized trial. Lancet2016; 387: 53–60.
3.
GrinsztejnBHoaglandBMoreiraRI, et al.Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in Brasil: 48 week results of a demonstration study. Lancet HIV2018; 5: e136–e146.
4.
BaetenJMDonnellDNdaseP, et al.Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med2012; 367(5): 399–410.
5.
MolinaJMCapitantCSpireB, et al.On-demand preexposure prophylaxis in men at high risk for HIV-1 infection list of authors. N Engl J Med2015; 373: 2237–2246.
6.
DesaiMFieldNGrantR, et al.Recent advances in pre-exposure prophylaxis for HIV. BMJ2017; 359: j5011. DOI: 10.1136/bmj.j5011.
7.
Emtricitabine/Tenofovir Disoproxil Fumarate. Micromedex (accessed October 10, 2021).
8.
Emtricitabine/Tenofovir Disoproxil Fumarate. Lexicomp (accessed October 10, 2021).
9.
HaskelbergHHoyJFAminJ, et al.Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One2012; 7(6): e38377. DOI: 10.1371/journal.pone.0038377.
10.
McComseyGAKitchDDaarES, et al.Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis2011; 203(12): 1791–1801. DOI: 10.1093/infdis/jir188.
11.
StellbrinkHJOrkinCArribasJR, et al.Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis2010; 51(8): 963–972. DOI: 10.1086/656417.
12.
BaranekBWangSCheungAM, et al.The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. Antivir Ther2020; 25(1): 21–32. DOI: 10.3851/IMP3346.
KriegerN.Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health1992; 82: 703–710.
15.
BieszkNPatelRHeaberlinA, et al.Detection of medication nonadherence through review of pharmacy claims data. Am J Health Syst Pharm2003; 60: 360–366.
16.
HorbergMAHurleyLBSilverbergMJ, et al.P. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr2007; 44: 531–539.
17.
ByrdKHouJHazenR, et al.Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr2019; 82(3): 245–251. DOI: 10.1097/QAI.0000000000002142.
18.
ByrdKKHouJGBushT, et al.Adherence and viral suppression among participants of the patient-centered Human Immunodeficiency Virus (HIV) care model project: a collaboration between community-based pharmacists and HIV clinical providers. Clin Infect Dis2020; 70(5): 789–797. DOI: 10.1093/cid/ciz276.
MigliaccioSGrecoEAFornariR, et al.Is obesity in women protective against osteoporosis?Diabetes Metab Syndr Obes2011; 4: 273–282. DOI: 10.2147/DMSO.S11920.
21.
CaoJJ. Effects of obesity on bone metabolism. J Orthop Surg Res2011; 6: 30. DOI: 10.1186/1749-799X-6-30.
22.
TangZHXiaoPLeiSF, et al.A bivariate whole-genome linkage scan suggests several shared genomic regions for obesity and osteoporosis. J Clin Endocrinol Metab2007; 92(7): 2751–2757. DOI: 10.1210/jc.2006-2607.
23.
TebasPPowderlyWGClaxtonS, et al.Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS2000; 14(4): F63–F67. DOI: 10.1097/00002030-200003100-00005.
24.
ViganòAMoraS. Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin Drug Saf2004; 3(3): 199–208. DOI: 10.1517/14740338.3.3.199.
25.
MadedduGSpanuASolinasP, et al.Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging2004; 48(1): 39–48.
26.
ArpadiSMHorlickMThorntonJ, et al.Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr2002; 29(5): 450–454. DOI: 10.1097/00126334-200204150-00004.
27.
CastilloABTarantalAFWatnikMR, et al.Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res2002; 20(6): 1185–1189. DOI: 10.1016/S0736-0266(02)00074-8.
28.
PurdyJBGafniRIReynoldsJC, et al.Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr2008; 152(4): 582–584. DOI: 10.1016/j.jpeds.2007.12.020.
29.
HazraRGafniRIMaldarelliF, et al.Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics2005; 116(6): e846–e854. DOI: 10.1542/peds.2005-0975.
30.
SpinelliMAGliddenDVAndersonPL, et al.Impact of Estimated Pre-Exposure Prophylaxis (PrEP) adherence patterns on bone mineral density in a large PrEP demonstration project. AIDS Res Hum Retroviruses2019; 35(9): 788–793. DOI: 10.1089/AID.2018.0297.
31.
KohlerJJHosseiniSHHoying-BrandtA, et al.Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest2009; 89(5): 513–519. DOI: 10.1038/labinvest.2009.14.
32.
VidalFDomingoJCGuallarJ, et al.In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother2006; 50(11): 3824–3832. DOI: 10.1128/AAC.00437-06.
33.
GrigsbyIFPhamLManskyLM, et al.Tenofovir-associated bone density loss. Ther Clin Risk Manag2010; 6: 41–47.
34.
ThomasJDohertySM. HIV infection--a risk factor for osteoporosis. J Acquir Immune Defic Syndr2003; 33(3): 281–291. DOI: 10.1097/00126334-200307010-00001.
35.
MondyKPowderlyWGClaxtonSA, et al.Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr2005; 38(4): 426–431. DOI: 10.1097/01.qai.0000145352.04440.1e.
36.
KanisJAMcCloskeyEV. Risk factors in osteoporosis. Maturitas1998; 30(3): 229–233. DOI: 10.1016/s0378-5122(98)00090-5.
37.
LaneNE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol2006; 194(2 Suppl): S3–S11. DOI: 10.1016/j.ajog.2005.08.047.
38.
FeldsteinAElmerPJSmithDH, et al.Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc2006; 54(3): 450–457. DOI: 10.1111/j.1532-5415.2005.00618.x.
DonnellDBaetenJMBumpusNN, et al.HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr2014; 66(3): 340–348. DOI: 10.1097/QAI.0000000000000172.
41.
ThomsonKBaetenJMugoN, et al.Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS2016; 11(1): 18–26. DOI: 10.1097/COH.0000000000000207.
StansfieldSMooreMBoilyMC, et al.Estimating benefits from using on-demand oral PrEP by MSM in US: a modeling study. In: Presented at Conference on Retroviruses and Opportunistic Infections, Virtual Conference, 14 February 2022. Available at: https://www.croiconference.org/search-abstracts/.
44.
AntoniGTremblayCDelaugerreC, et al.On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV2020; 7(2): e113–e120. DOI: 10.1016/S2352-3018(19)30341-8.
